CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank58
3Y CAGR+22.6%
5Y CAGR-34.4%
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

3Y CAGR
+22.6%/yr
Annual compound
5Y CAGR
-34.4%/yr
Recent acceleration
Percentile
P58
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202512.40%
2024-52.16%
202349.46%
20226.72%
2021-4189.49%
2020102.05%
2019-81.54%
2018-146.98%
20174111.74%
201685.49%